M-End PE Interactions
There are 688 drugs known to interact with M-End PE (brompheniramine/codeine/phenylephrine), along with 24 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 148 are major, 537 are moderate, and 3 are minor.
- View all 688 medications that may interact with M-End PE
- View M-End PE alcohol/food interactions (1)
- View M-End PE disease interactions (24)
Most frequently checked interactions
View interaction reports for M-End PE (brompheniramine / codeine / phenylephrine) and the medicines listed below.
- acetaminophen
- Afrin Original (oxymetazoline nasal)
- albuterol
- cetirizine
- dicyclomine
- Ex-Lax (senna)
- Fish Oil (omega-3 polyunsaturated fatty acids)
- melatonin
- meloxicam
- methocarbamol
- montelukast
- Norco (acetaminophen / hydrocodone)
- Prilosec OTC (omeprazole)
- pseudoephedrine
- ranitidine
- tramadol
- venlafaxine
- Vitamin B6 (pyridoxine)
M-End PE alcohol/food interactions
There is 1 alcohol/food interaction with M-End PE (brompheniramine / codeine / phenylephrine).
M-End PE disease interactions
There are 24 disease interactions with M-End PE (brompheniramine / codeine / phenylephrine) which include:
- impaired GI motility
- infectious diarrhea
- prematurity
- acute alcohol intoxication
- drug dependence
- hypotension
- intracranial pressure
- respiratory depression
- gastrointestinal obstruction
- cardiovascular disease
- anticholinergic effects
- asthma/COPD
- cardiovascular
- renal/liver disease
- adrenal insufficiency
- liver disease
- renal dysfunction
- seizure disorders
- urinary retention
- arrhythmias
- biliary tract disease
- BPH
- diabetes
- glaucoma
Report options
More about M-End PE (brompheniramine / codeine / phenylephrine)
- M-End PE consumer information
- Compare alternatives
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: upper respiratory combinations
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.